Sanofi to invest $474M annually on mRNA vaccine R&D

By The Science Advisory Board staff writers

June 30, 2021 -- Sanofi will spend approximately 400 million euros ($474 million U.S.) to accelerate the research and development (R&D) of messenger RNA (mRNA) vaccines.

The company will accelerate vaccine work through its newly launched vaccines mRNA Center of Excellence, which will consist of 400 employees from sites in Massachusetts and France working to deliver next-generation mRNA vaccines against unmet diseases.

The teams will focus on R&D, digital, and chemistry, manufacturing and controls (CMC) of mRNA vaccines in both locations. By 2025, Sanofi hopes to have six clinical vaccine candidates.

Millennium Technology Prize awarded to NGS pioneers
The Technology Academy Finland awarded the 2020 Millennium Technology Prize to Shankar Balasubramanian, PhD, and David Klenerman, PhD, chemists from Cambridge...
Sanofi, GSK COVID-19 vaccine to advance to phase III trials
Sanofi and GlaxoSmithKline's (GSK's) adjuvanted, recombinant COVID-19 vaccine candidate produced strong rates of neutralizing antibody responses in all...
Cellectis, Sanofi partner on UCART clinical trials
Sanofi has agreed to supply anti-CD52 monoclonal antibody alemtuzumab for use in a lymphodepleting regimen in Cellectis-sponsored universal chimeric antigen...
Sanofi, Stanford partner to study immunology
Sanofi has entered into a three-year research collaboration with the Stanford University School of Medicine to advance the understanding of immunology...
Sanofi to provide fill/finish services for Moderna COVID-19 vaccine
Moderna has inked a new agreement with Sanofi in order to scale up U.S. manufacturing capacity for its COVID-19 vaccine.

Copyright © 2021

Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter